PMDS.ST Stock Analysis
PM
Uncovered
PMD Device Solutions AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.008
Dividend yield
—
Shares outstanding
20.849 B
PMD Device Solutions AB operates as a medical technology company. The company is headquartered in Solna, Stockholm. The company went IPO on 2017-07-06. The firm deals with research, development and production of medical technical products and equipment and related activities. The company specializes in the development of therapeutic peptides for the bioactive wound care market. The firm possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.